Cowen Inc’s Celldex Therapeutics CLDX Stock Holding History

Cowen Inc’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-2,000	Closed	-$114K	–	227
2016 Q1	$114K	Buy	+2,000	New	+$225K	﹤0.01%	234

Other funds holding CLDX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BIM

Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return

Cowen Inc's CLDX Position: Q2 2016 in Review

Cowen Inc sold out of Celldex Therapeutics (CLDX) in Q2 2016, closing a stake of 683 shares — an estimated $39K sold.

Cowen Inc first reported a position in CLDX in Q1 2016 and held it in 1 quarter. The position peaked at $39K in Q1 2016. 141 funds tracked by Wall St. Rank hold CLDX as of Q2 2016.

Cowen Inc reported no remaining Celldex Therapeutics position as of Q2 2016 after selling out during the quarter.
Cowen Inc sold 683 Celldex Therapeutics shares in Q2 2016, an estimated $39K.
Cowen Inc first reported a position in Celldex Therapeutics in Q1 2016 and held it in 1 quarter.
Cowen Inc's Celldex Therapeutics position peaked at $39K in Q1 2016.
141 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2016.

Based on Cowen Inc's 13F filing for Q2 2016, filed 10 Aug 2016.